Primary Site >> Pancreatic Cancer

Gene >> ERBB3

  • 1996
  • 1999
  • 2004
  • 2006
  • 2007
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
Ref: Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors.
PMID: 8834768
Ref: Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas.
PMID: 10615931
Ref: Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.
PMID: 15585383
Ref: [(11)C]N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
PMID: 20641864
Ref: Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer.
PMID: 16424038
Ref: Expression and differential signaling of heregulins in pancreatic cancer cells.
PMID: 17096356
Ref: ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
PMID: 17457047
Ref: Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1.
PMID: 17671194
Ref: HER-family gene amplification and expression in resected pancreatic cancer.
PMID: 19304440
Ref: Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
PMID: 20103665
Ref: ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
PMID: 20647770
Ref: Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.
PMID: 20726858
Ref: Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.
PMID: 21110957
Ref: Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.
PMID: 21792199
Ref: HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer.
PMID: 22067729
Ref: Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells.
PMID: 22977607
Ref: Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
PMID: 22213458
Ref: The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways.
PMID: 22393391
Ref: Targeting EGFR in pancreatic cancer treatment.
PMID: 22458527
Ref: Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer.
PMID: 22761868
Ref: HER3 overexpression and survival in solid tumors: a meta-analysis.
PMID: 23221996
Ref: Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines.
PMID: 23320098
Ref: Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.
PMID: 23918833
Ref: Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.
PMID: 24791013
Ref: The ErbB/HER family of protein-tyrosine kinases and cancer.
PMID: 24269963
Ref: Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation.
PMID: 24810090
Ref: Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.
PMID: 25133484
Ref: HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
PMID: 25216528
Ref: HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.
PMID: 25941588
Ref: Examination of HER3 targeting in cancer using monoclonal antibodies.
PMID: 25564668
Ref: Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
PMID: 25992771
Ref: Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells.
PMID: 26035354
Ref: Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.
PMID: 26287187
Ref: The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.
PMID: 26464195
Ref: Pertuzumab in gastrointestinal cancer.
PMID: 26619359
Ref: Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.
PMID: 26668065
Ref: Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma.
PMID: 27070783
Ref: Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation.
PMID: 27609096
Ref: The prospect of patritumab for treating non-small cell lung cancer.
PMID: 27744717
Ref: MicroRNA-148a Suppresses the Proliferation and Migration of Pancreatic Cancer Cells by Down-regulating ErbB3.
PMID: 27776045
Ref: The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.
PMID: 27871278
Ref: Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
PMID: 28507002
Ref: Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
PMID: 29549161
Ref: Imaging EGFR and HER3 through (89)Zr-labeled MEHD7945A (Duligotuzumab).
PMID: 29899472
Ref: Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
PMID: 29935372
Ref: Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors.
PMID: 30384408